Publications by authors named "R Kissling"
Article Synopsis
- The study investigates the oxygen content in perfluorohexyloctane (PFHO), an FDA-approved eye drop for treating dry eye disease, highlighting its efficacy and properties.* -
- Using fluorine-19 nuclear magnetic resonance spectroscopy, researchers measured T1 relaxation times and found that PFHO has a substantial level of oxygen compared to natural tears.* -
- Results suggest that PFHO does not hinder the oxygen needed for corneal health and may provide beneficial oxygen to aid healing in patients with dry eye.*
Article Synopsis
- PFHO (perfluorohexyloctane) MIEBO is a water-free eye drop approved for treating dry eye disease and shows significant potential in reducing the evaporation rate of saline in lab tests.
- In experiments, PFHO decreased the evaporation rate by up to 88% when layered over saline, outperforming common artificial tears and demonstrating its effectiveness at both 25°C and 35°C.
- The findings suggest that PFHO could potentially replace the natural lipid layer in the tear film, providing a new option for patients suffering from dry eye disease.
Background: Since the publication of Standard Method Performance Requirements (SMPR®) for vitamin D in infant formula (SMPR 2011.004) by AOAC INTERNATIONAL, revised vitamin D limits have been recommended by the European Food Safety Authority (EFSA) for infant formula and adopted in Commission Delegated Regulation (EU) 2019/828. The vitamin D range introduced, 2-2.
View Article and Find Full Text PDFBackground: To evaluate the safety of flibanserin in premenopausal and naturally postmenopausal women with hypoactive sexual desire disorder (HSDD) in an open-label extension (OLE) study.
Aim: To examine the safety and tolerability of flibanserin 100 mg once daily at bedtime in the treatment of premenopausal and naturally postmenopausal women with HSDD in a multicenter 28-week OLE study.
Methods: Patients entering this study received flibanserin or placebo in the double-blinded, placebo-controlled trials of premenopausal and postmenopausal women and in a pharmacokinetic study of postmenopausal women.
Background: Depression is often associated with sexual dysfunction, and pharmacologic treatment for hypoactive sexual desire disorder can be considered in women receiving treatment for depression.
Aim: To evaluate the safety of flibanserin in women treated for depression with selective serotonin reuptake inhibitors or serotonin and norepinephrine reuptake inhibitors.
Methods: In this double-blinded, randomized, placebo-controlled trial, women with remitted or mild depression treated with selective serotonin reuptake inhibitors or serotonin and norepinephrine reuptake inhibitors who were not postmenopausal and were experiencing symptoms of hypoactive sexual desire disorder (ie, decreased sexual desire and related distress) received flibanserin 50 mg at bedtime (qhs) for 2 weeks and up-titrated to 100 mg qhs, flibanserin 100 mg qhs for the entire treatment period, or placebo for up to 12 weeks.